Siglec-15 antibody–GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophages

Siglec-15 antibody–GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophages

Background Sialic acid-binding immunoglobulin-like lectin (Siglec)-15-expressing tumor-associated macrophages (TAMs) drive immunosuppression in the tumor microenvironment (TME), promoting CD8+ T cell exhaustion and limiting immunotherapy efficacy. Both blockade of immune checkpoint molecule Siglec-1...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jun Li, Hongyan Li, Zemeng Ma, Xiaoyao Hao, Wenwen Dai, Jinyu Liu, Mingjiu Chen, Shuang Qu, Quanli Zhang, Jiajing Luo, Shouyong Gu, Dihan Zhu, Ke Zen
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-04-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/4/e010580.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Reprogramming of GM-CSF-dependent alveolar macrophages through GSK3 activity modulation
by: Israel Ríos, et al.
Published: (2025-05-01)

Synergistic effects of cryoablation and GM-CSF in colorectal liver metastases management in tumor-bearing mice
by: Junfeng Wang, et al.
Published: (2025-05-01)

Prolonged Survival of Neutrophils Induced by Tumor‐Derived G‐CSF/GM‐CSF Promotes Immunosuppression and Progression in Laryngeal Squamous Cell Carcinoma
by: Xiaoke Zhu, et al.
Published: (2024-12-01)

Development of Dendritic Cells from GM-CSF-/-Mice invitro : GM-CSF Enhances Productionand Survival of Cells
by: Keping Ni, et al.
Published: (2001-01-01)

Oncolytic adenovirus inhibits TNBC tumor growth/metastasis in mice by targeting TGFB and overexpressing GM-CSF
by: Nguyễn Thị Thanh Nhàn, et al.
Published: (2025-03-01)

Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment
by: Shih-Jen Liu, et al.
Published: (2021-10-01)

Engineered GM-CSF polarizes protumorigenic tumor-associated macrophages to an antitumorigenic phenotype and potently synergizes with IL-12 immunotherapy
by: Yue Wang, et al.
Published: (2024-12-01)

Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma
by: Yuchen Zhang, et al.
Published: (2025-01-01)

Decreased melanoma CSF-1 secretion by Cannabigerol treatment reprograms regulatory myeloid cells and reduces tumor progression
by: Iris Wyrobnik, et al.
Published: (2023-12-01)

Stimulus-activated ribonuclease targeting chimeras for tumor microenvironment activated cancer therapy
by: Yuqi Zhang, et al.
Published: (2025-02-01)

High-altitude hypoxia exacerbates chemotherapy-induced myelosuppression by lowering serum G-CSF/GM-CSF and regulating apoptosis and proliferation
by: Jing Shi, et al.
Published: (2025-05-01)

Metabolic reprogramming of hypoxic tumor-associated macrophages through CSF-1R targeting favors treatment efficiency in colorectal cancers
by: Arnaud Millet, et al.
Published: (2024-09-01)

Role of GM-CSF in normalizing the effect of Uremic Toxins on Neutrophil Apoptosis and Function
by: Nariman Zahran, et al.
Published: (2014-08-01)

The effect of GM-CSF and predictors of treatment outcome in pediatric septic shock patients
by: Zhen-Hao Yu, et al.
Published: (2025-02-01)

Potentiating T cell tumor targeting using a combination of TCR with a Siglec-7 based CSR
by: Shiran Didi-Zurinam, et al.
Published: (2025-05-01)

Controlling tumor progression and recurrence in mice through combined treatment with a PD-L1 inhibitor and a designer Salmonella strain that delivers GM-CSF
by: Heung Jin Jeon, et al.
Published: (2024-12-01)

GM-CSF and IL-21-armed oncolytic vaccinia virus significantly enhances anti-tumor activity and synergizes with anti-PD1 immunotherapy in pancreatic cancer
by: Yujing Xuan, et al.
Published: (2025-01-01)

Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin
by: Richard E Kast, et al.
Published: (2017-04-01)

Colonic growth factors (G-CSF, GM-CSF) and chemokines (MCP-1, MIP-1β) in severe ulcerative colitis
by: Yevgeny A. Konovich, et al.
Published: (2018-08-01)

Siglec6 CAR T cells suppressed progression of AML via inhibiting Siglec6 and SHP2 induced Src and ERK signaling activation
by: Qian Li, et al.
Published: (2025-05-01)

Exogenous GM-CSF therapy for autoimmune pulmonary alveolar proteinosis: a systematic literature review
by: Wushu Chen, et al.
Published: (2025-05-01)

Correction: Metabolic reprogramming of hypoxic tumor-associated macrophages through CSF-1R targeting favors treatment efficiency in colorectal cancers
Published: (2024-11-01)

Pulmonary Alveolar Proteinosis Refractory to Plasmapheresis and Rituximab despite GM-CSF Antibody Reduction
by: Aysenur Keske, et al.
Published: (2022-01-01)

M-CSF and GM-CSF Regulation of STAT5 Activation and DNA Binding in Myeloid Cell Differentiation is Disrupted in Nonobese Diabetic Mice
by: B. Rumore-Maton, et al.
Published: (2008-01-01)

Comprehensive Modular Synthesis of Ganglioside Glycans and Evaluation of their Binding Affinities to Siglec‐7 and Siglec‐9
by: Avijit K. Adak, et al.
Published: (2025-01-01)

Recombinant human granulocyte-macrophage colony-stimulating factor therapy and endogenous plasma GM-CSF, IL-3, IL-4 concentrations in pediatric patients with solid tumors
by: N Cetingül, et al.
Published: (1997-10-01)

Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors
by: Dmitriy Zamarin, et al.
Published: (2024-11-01)

Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Downregulates the Expression of Protumor Factors Cyclooxygenase-2 and Inducible Nitric Oxide Synthase in a GM-CSF Receptor-Independent Manner in Cervical Cancer Cells
by: Nanyan Jiang, et al.
Published: (2015-01-01)

Siglec‐G Suppresses CD8+ T Cells Responses through Metabolic Rewiring and Can be Targeted to Enhance Tumor Immunotherapy
by: Shenhui Yin, et al.
Published: (2024-12-01)

Corrigendum: Exogenous GM-CSF therapy for autoimmune pulmonary alveolar proteinosis: a systematic literature review
by: Wushu Chen, et al.
Published: (2025-06-01)

Neoplastic Meningitis: How MRI and CSF Cytology Are Influenced by CSF Cell Count and Tumor Type
by: P. Prömmel, et al.
Published: (2013-01-01)

Insights into CSF-1R Expression in the Tumor Microenvironment
by: Caterina Tomassetti, et al.
Published: (2024-10-01)

Determination of an Optimal Concentration of GM-CSF for Improving Oocyte In vitro Maturation in a Mouse Model
by: Anmol Saini, et al.
Published: (2025-03-01)

GM-CSF production from human airway smooth muscle cells is potentiated by human serum
by: Maria B. Sukkar, et al.
Published: (2000-01-01)

Effect of Hypoxia on Siglec-7 and Siglec-9 Receptors and Sialoglycan Ligands and Impact of Their Targeting on NK Cell Cytotoxicity
by: Husam Nawafleh, et al.
Published: (2024-10-01)

The Effects of Paracoccidioides brasiliensis Infection on GM-CSF- and M-CSF-Induced Mouse Bone Marrow-Derived Macrophage from Resistant and Susceptible Mice Strains
by: Calliandra de Souza Silva, et al.
Published: (2015-01-01)

Rational design of FVIII sialylated peptides to target Siglec-3 and Siglec-9 and improve peptide formulations for reverse vaccines
by: Eleonora Nardini, et al.
Published: (2025-04-01)

Pharmacologic inhibition of CSF-1R suppresses intrinsic tumor cell growth in osteosarcoma with CSF-1R overexpression
by: Cheng Dai, et al.
Published: (2025-08-01)

Siglec-9+ tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer
by: Yan Huang, et al.
Published: (2023-09-01)

Metabolic reprogramming of tumor-associated neutrophils in tumor treatment and therapeutic resistance
by: Jun Lin, et al.
Published: (2025-04-01)